Fumarranol

Fumarranol

Identifiers
IUPAC name (1S,5S)-5-(hydroxymethyl)-1-methoxy-6-[(2R,3R)-2-methyl-3-(3-methylbut-2-enyl)oxiran-2-yl]bicyclo[3.1.0]hexan-2-one
JSmol)	Interactive image
SMILES CC(=CC[C@@H]1[C@@](O1)(C)C2[C@]3([C@@]2(C(=O)CC3)OC)CO)C
InChI InChI=1S/C16H24O4/c1-10(2)5-6-12-14(3,20-12)13-15(9-17)8-7-11(18)16(13,15)19-4/h5,12-13,17H,6-9H2,1-4H3/t12-,13?,14+,15-,16+/m1/s1 Key:CANZHCRPLGNWCR-LMINUHAASA-N

Fumarranol is a drug which acts as an inhibitor of the type 2 methionine aminopeptidase enzyme METAP2. It was derived by structural modification of the natural product fumagillin. It was originally developed as an anti-angiogenesis drug for the treatment of cancer,^[1] but it was subsequently found to bind with high affinity to the METAP2 enzyme in malaria parasites and has been investigated as a potential treatment for malaria.^[2][3]

See also

• Beloranib

References

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

• v
• t
• e